

Data Sheet

Target: Autophagy; HBV

Pathway: Anti-infection; Autophagy

Solubility: DMSO: 100 mg/mL (256.19 mM; Need ultrasonic)

390.34

BIOLOGICAL ACTIVITY:

Molecular Weight:

Bicyclol(SY 801) is a anti-hepatitis drug. Target: HBV Oral administration of bicyclol normalized the elevated serum transaminases (ALT, AST) by approximately 50% in chronic viral hepatitis B and C, and also showed certain level of inhibiting HBV and HCV replication. No noticeable adverse reaction has been observed. In combination therapy of bicyclol with interferon alpha, lamivudine and adefovir dipivoxil in HBV or HCV, bicyclol may potentiate the anti-viral efficacy and reduce YMDD mutant and side effects. In 2004 China FDA issued license to manufacture bicyclol. Since then bicyclol has been widely used to treat chronic HBV and HCV in China [1].

References:

[1]. Walsh, S.W., Y. Wang, and A. Killian, AA-2414, an antioxidant and thromboxane receptor blocker, completely inhibits peroxide-induced vasoconstriction in the human placenta. J Pharmacol Exp Ther, 1999. 290(1): p. 220-6.

CAIndexNames:

[4,4'-Bi-1,3-benzodioxole]-5-carboxylic acid, 5'-(hydroxymethyl)-7,7'-dimethoxy-, methyl ester

SMILES:

 ${\sf O=C(C1=CC(OC)=C(OCO2)C2=C1C3=C4OCOC4=C(OC)C=C3CO)OC}$

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr. Suite Q. Monmouth Junction, NJ 08852, USA

Page 1 of 1 www.ChemScene.com